beta-lapachone has been researched along with Carcinoma, Non-Small Cell Lung in 10 studies
beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase
beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lung cancer is one of the most lethal forms of cancer and current chemotherapeutic strategies lack broad specificity and efficacy." | 1.42 | Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy. ( Boothman, DA; Gao, J; Hammer, S; Huang, G; Huang, X; Kilgore, JA; Ma, X; Moore, Z; Wang, Y; Williams, NS, 2015) |
| "Lung cancer is the leading cause of cancer-related death worldwide, and non-small cell lung cancer (NSCLC) is the most common pathological type with a reported frequency of about 85% of all cases." | 1.42 | Beta-Lapachone Suppresses Non-small Cell Lung Cancer Proliferation through the Regulation of Specificity Protein 1. ( Bang, W; Chae, JI; Choi, YH; Jeon, YJ; Shim, JH, 2015) |
| "4) or in 1 M sodium salicylate, which agrees with the desired dosing sequence of the two drugs to exert synergistic pharmacologic effect at different cell checkpoints." | 1.42 | β-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy as Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy. ( Chen, Z; Gao, J; Liu, C; Qian, F; Yang, K; Zhang, L, 2015) |
| "Lung cancer is the leading cause of cancer-related deaths with current chemotherapies lacking adequate specificity and efficacy." | 1.36 | Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. ( Bey, EA; Blanco, E; Boothman, DA; Bornmann, WG; Carnevale, KA; Chen, H; Gao, J; Kessinger, CW; Khemtong, C; Setti-Guthi, J; Yang, SG, 2010) |
| "Lung cancer is the number one cause of cancer-related deaths in the world." | 1.34 | An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. ( Bentle, MS; Bey, EA; Boothman, DA; Bornmann, WG; Dong, Y; Gao, J; Girard, L; Minna, JD; Reinicke, KE; Yang, CR, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bey, EA | 3 |
| Bentle, MS | 1 |
| Reinicke, KE | 1 |
| Dong, Y | 3 |
| Yang, CR | 1 |
| Girard, L | 1 |
| Minna, JD | 2 |
| Bornmann, WG | 2 |
| Gao, J | 4 |
| Boothman, DA | 5 |
| Zhang, X | 2 |
| Bian, J | 1 |
| Li, X | 2 |
| Wu, X | 2 |
| You, Q | 2 |
| Li, Z | 1 |
| Yu, Y | 1 |
| Torrente, L | 1 |
| Prieto-Farigua, N | 1 |
| Falzone, A | 1 |
| Elkins, CM | 1 |
| Haura, EB | 1 |
| DeNicola, GM | 1 |
| Ma, X | 1 |
| Huang, X | 2 |
| Moore, Z | 1 |
| Huang, G | 1 |
| Kilgore, JA | 2 |
| Wang, Y | 1 |
| Hammer, S | 1 |
| Williams, NS | 2 |
| Jeon, YJ | 1 |
| Bang, W | 1 |
| Choi, YH | 1 |
| Shim, JH | 1 |
| Chae, JI | 1 |
| Zhang, L | 1 |
| Chen, Z | 1 |
| Yang, K | 1 |
| Liu, C | 1 |
| Qian, F | 1 |
| Liu, HY | 1 |
| Li, QR | 1 |
| Cheng, XF | 1 |
| Wang, GJ | 1 |
| Hao, HP | 1 |
| Motea, EA | 1 |
| Moore, ZR | 1 |
| Yao, J | 1 |
| Chakrabarti, G | 1 |
| Silvers, MA | 1 |
| Patidar, PL | 1 |
| Cholka, A | 1 |
| Fattah, F | 1 |
| Cha, Y | 1 |
| Anderson, GG | 1 |
| Kusko, R | 1 |
| Peyton, M | 1 |
| Yan, J | 1 |
| Xie, XJ | 1 |
| Sarode, V | 1 |
| Beg, M | 1 |
| Gerber, DE | 1 |
| Blanco, E | 1 |
| Khemtong, C | 1 |
| Yang, SG | 1 |
| Setti-Guthi, J | 1 |
| Chen, H | 1 |
| Kessinger, CW | 1 |
| Carnevale, KA | 1 |
10 other studies available for beta-lapachone and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Human | 2007 |
2-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Proliferat | 2017 |
Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug R | 2018 |
Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance | 2020 |
Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Comet Assay; Eryth | 2015 |
Beta-Lapachone Suppresses Non-small Cell Lung Cancer Proliferation through the Regulation of Specificity Protein 1.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, | 2015 |
β-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy as Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy.
Topics: Anti-Infective Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, N | 2015 |
NAMPT inhibition synergizes with NQO1-targeting agents in inducing apoptotic cell death in non-small cell lung cancer cells.
Topics: Abietanes; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytokines; Enzyme Inhibitors | 2016 |
Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Da | 2016 |
Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Carriers; Fem | 2010 |